New study aims to catch diabetic eye disease before it steals sight
NCT ID NCT07458516
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 100 people with type 2 diabetes who have moderate to severe diabetic retinopathy, a condition that can lead to vision loss. Researchers will use advanced eye scans and imaging to track changes in the retina over two years. The goal is to find better ways to predict when treatment is needed to prevent blindness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors identify the right time to treat diabetic retinopathy, potentially preventing vision loss in people with type 2 diabetes.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new drug or therapy, and the findings may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AIBILI-CEC (AIBILI-Clinical Trial Centre)
RECRUITINGCoimbra, 3000-548, Portugal
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••